Potential Effects of the FLT3-ITD Mutation on Chemotherapy Response and Prognosis of Acute Promyelocytic Leukemia

References

• Lucena-Araujo AR, Kim HT, Jacomo RH, et al. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol. 2014;93:2001–2010. doi:10.1007/s00277-014-2142-924981688
   PubMed Web of Science ®Google Scholar
• Souza Melo CP, Campos CB, Dutra ÁP, et al. Correlation between FLT3-ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias. Leuk Res. 2015;39:131–137. doi:10.1016/j.leukres.2014.11.01025530565
   PubMed Web of Science ®Google Scholar
• Beitinjaneh A, Jang S, Roukoz H, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 2010;34:831–836. doi:10.1016/j.leukres.2010.01.00120096459
   PubMed Web of Science ®Google Scholar
• Fan Y, Cao Y, Bai X, et al. The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia. Hematology. 2018;23(7):379–384. doi:10.1080/10245332.2017.141571729251252
   PubMed Web of Science ®Google Scholar
• Picharski GL, Andrade DP, Fabro ALMR, et al. The impact of Flt3 gene mutations in acute promyelocytic leukemia: a meta-analysis. Cancers (Basel). 2019;11(9):1311. doi:10.3390/cancers11091311
   PubMed Web of Science ®Google Scholar
• Lou Y, Ma Y, Suo S, et al. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy. Leuk Res. 2015;39(9):938–944. doi:10.1016/j.leukres.2015.05.01626183877
   PubMed Web of Science ®Google Scholar
• Cicconi L, Divona M, Ciardi C, et al. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia. 2016;30(10):1987–1992. doi:10.1038/leu.2016.12227133819
   PubMed Web of Science ®Google Scholar
• Poiré X, Moser BK, Gallagher RE, et al. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014;55(7):1523–1532. doi:10.3109/10428194.2013.84298524160850
   PubMed Web of Science ®Google Scholar
• Cécile E, Ramy R, Kim LR, et al. FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias. Blood. 2019;133(13):1495–1506. doi:10.1182/blood-2018-07-86609530674471
   PubMed Web of Science ®Google Scholar
• Zhang ZN, Shen T. The Third Edition of the Criteria for Diagnosis and Efficacy of Blood Diseases. Beijing Science Press; 2007:106–116.
   Google Scholar
• Zhang SJ, Li JY, Shi JY. Study on FLT3 gene mutations in acute myeloid leukemia. Chin J Hematol. 2007;28:124–126.
   Google Scholar
• Han YL, Zhang SJ, Qiao C, et al. Study on FLT3 gene mutation in acute myeloid leukemia. Chin J Exp Hematol. 2009;17(5):1135–1139.
   Google Scholar
• Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247–1253.10942364
   PubMed Web of Science ®Google Scholar
• Barragán E, Montesinos P, Camos M, et al. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica. 2011;96:1470–1477. doi:10.3324/haematol.2011.04493321685470
   PubMed Web of Science ®Google Scholar
• Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133:1630–1643. doi:10.1182/blood-2019-01-89498030803991
   PubMed Web of Science ®Google Scholar
• Gale RE, Hills R, Pizzey AR, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106(12):3768–3776. doi:10.1182/blood-2005-04-174616105978
   PubMed Web of Science ®Google Scholar
• Gong BF, Wang Y, Lin D, et al. Analysis of FLT3-ITD mutation in acute promyelocytic leukemia. Chin J Exp Hematol. 2016;24(6):1615–1621. doi:10.7534/j.issn.1009-2137.2016.06.001
   Google Scholar
• Xu HL. The clinical significance of FLT3 gene mutation in acute promyelocytic leukemia. China Modern Med Appl. 2016;10(8):27–28.
   Google Scholar
• Westervelt P, Ley TJ. Seed versus soil: the importance of the target cell for transgenic models of human leukemias. Blood. 1999;93:2143–2148. doi:10.1182/blood.V93.7.214310090920
   PubMed Web of Science ®Google Scholar
• Grimwade D, Enver T. Acute promyelocytic leukemia: where does it stem from? Leukemia. 2004;18:375–384. doi:10.1038/sj.leu.240323414737069
   PubMed Web of Science ®Google Scholar
• Kelly L, Kutok J, Williams I, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A. 2002;99(12):8283–8288. doi:10.1073/pnas.12223369912060771
   PubMed Web of Science ®Google Scholar
• Le Beau MM, Davis EM, Patel B, et al. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia. Blood. 2003;102(3):1072–1074. doi:10.1182/blood-2003-01-015512689927
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res. 2009;15(13):4263–4269. doi:10.1158/1078-0432.CCR-08-112319549778
   PubMed Web of Science ®Google Scholar
• Spiekermann K, Bagrintseva K, Schwab R, et al. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res. 2003;9(6):2140–2150.12796379
   PubMed Web of Science ®Google Scholar
• Shen Y, Fu YK, Zhu YM, et al. Mutations of epigenetic modifier genes as a poor prognostic factor in acute promyelocytic leukemia under treatment with all-trans retinoic acid and arsenic trioxide. EBio Med. 2015;2(6):563–571.
   PubMed Web of Science ®Google Scholar
• Hong SD, Kim YK, Kim HN, et al. Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients. Korean J Hematol. 2011;46(1):24–30. doi:10.5045/kjh.2011.46.1.2421461300
   PubMedGoogle Scholar
• Kutny MA, Moser BK, Laumann K, et al. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from Children’s Oncology Group. Pediatr Blood Cancer. 2012;59:662–667. doi:10.1002/pbc.2412222378655
   PubMed Web of Science ®Google Scholar
• Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775–783. doi:10.1182/blood-2008-07-16861718945964
   PubMed Web of Science ®Google Scholar
• Jeddi R, Ghédira H, Mnif S, et al. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res. 2010;34(4):545–547. doi:10.1016/j.leukres.2009.09.01719800119
   PubMed Web of Science ®Google Scholar
• Breccia M, Loglisci G, Loglisci MG, et al. FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. Haematologica. 2013;98(12):e161–e163. doi:10.3324/haematol.2013.09538024323990
   PubMed Web of Science ®Google Scholar
• Gale RE, Hills R, Pizzey A, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106:3768–3778.16105978
   PubMed Web of Science ®Google Scholar
• Molica M, Breccia M. FLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosis. Leuk Res. 2015;39(4):397–399. doi:10.1016/j.leukres.2015.01.00425666257
   PubMed Web of Science ®Google Scholar
• Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci. 2009;106:3342–3347. doi:10.1073/pnas.081328010619225113
   PubMed Web of Science ®Google Scholar
• Fathi AT, Chen YB. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. Eur J Haematol. 2017;98(4):330–336. doi:10.1111/ejh.1284128000291
   PubMed Web of Science ®Google Scholar